CRISM Therapeutics (LON:CRTX – Get Free Report) issued its earnings results on Monday. The company reported GBX (2.60) earnings per share (EPS) for the quarter, Digital Look Earnings reports.
CRISM Therapeutics Stock Up 0.5%
LON:CRTX opened at GBX 10 on Monday. CRISM Therapeutics has a 12-month low of GBX 8 and a 12-month high of GBX 18.50. The firm has a market capitalization of £7.92 million, a price-to-earnings ratio of -1.96 and a beta of 0.58. The stock’s 50 day moving average price is GBX 10.43 and its two-hundred day moving average price is GBX 11.15.
About CRISM Therapeutics
ChemoSeed, CRISM’s lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin.
Further Reading
- Five stocks we like better than CRISM Therapeutics
- 3 Software Stocks Rebounding as AI Fears Give Way to Growth
- NVIDIA Just Named AI’s Next Bottleneck—And These 3 Stocks Sit Right In It
- Gold Has Gone Sideways, But These 3 Stocks Haven’t
- The AI Bottleneck Is Not Chips Anymore and 3 Pipeline Stocks Are Cashing In
Receive News & Ratings for CRISM Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISM Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
